Compass Therapeutics appoints Sapna Mehtani as vice president and head of intellectual property

Compass Therapeutics appoints Sapna Mehtani as vice president and head of intellectual property
Compass Therapeutics adds vice president

Compass Therapeutics has announced the appointment of Sapna Mehtani as vice president and head of intellectual property.

The addition brings new leadership to the company’s strategy in managing its intellectual property portfolio.

Compass Therapeutics recently presented results from its Phase 2 3 COMPANION 002 trial in advanced biliary tract cancer at ESMO 2026. The study focused on patients with advanced disease. The company continues to advance its pipeline alongside new management appointments.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.